Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Peakadilly nv biopharmaceutical firm created

18.10.2004


The Flanders Interuniversity Institute for Biotechnology (VIB) and Ghent University have started up a new biopharmaceutical company named Peakadilly nv. Peakadilly will develop and market a new generation of molecular diagnostics − so-called protein bio-markers − using innovative proteomics technology developed by the research group under the direction of Joël Vandekerckhove. The markers can be used in the development of medicines, making the process much more efficient, effective and economical. The bio-markers will also enable doctors to detect diseases sooner and, because many medicines work effectively only with a limited group of patients, doctors will also be able to verify whether a particular medicine will work for certain patients. Peakadilly will be led by Koen Kas, who has been closely involved in the development of the technology platform.



Health care tailored to the patient

Today, it takes an average of 800 million euro and about 12 years to develop a new drug. Among other things, the time-consuming and expensive clinical studies test the safety and effectiveness of a potential medicine. Frequently, the studies indicate that the drug is not really effective at all, or only for a small number of patients. At present, nothing exists for measuring whether a candidate drug is truly effective during development. Bio-markers can bridge this gap and thus substantially lower the development costs and time.


Bio-markers will also make it possible to target therapies specifically to the patients for whom they are successful. Most drugs in the field of oncology, for example, help only a limited number of patients. Bio-markers will enable the appropriate therapy to be selected for the patient − a step toward patient-specific medicine. The bio-markers will also enable earlier detection of life-threatening diseases like cancer.

The impact of bio-markers for the patient − and, indirectly, for the social security system − will be profound. Whereas bio-markers are suitable and desired in every disease field, Peakadilly will initially focus on applications in oncology − operating at the interface of diagnostics and therapeutics.

The product of innovative proteomics technology

Proteins are responsible for all life processes in our cells − regulating the digestion of our food, communication between cells, and so on. Defects in (the activity of) particular proteins are at the basis of many diseases (such as diseases of the muscles and cancer), and the development of medicines focuses on restoring or positively affecting the proteins’ activity. Proteomics − the study of the proteome, or proteins in their entirety – is of crucial importance for this. The technology enables one to uncover all the differences between the proteome of a sick person and that of a healthy person, and between the proteome of a patient who reacts positively to a drug and of a patient who is not helped by it.

Proteomics can also provide insight into the origin and progression of diseases. The analysis of the effect of a drug on the proteome enables researchers to understand which protein(s) the drug acts upon. Until recently, however, there was no efficient way to study the proteome systematically. Pioneering research under the direction of Joël Vandekerckhove (Scientific Director of a VIB research department at Ghent University) has led to a technology that, for the first time, enables thousands of proteins to be analyzed in a systematic way.

Peakadilly will apply this proteomics technology to identify specific proteins and protein profiles that are related to a disease or the activity of a candidate drug. Then, with this knowledge, Peakadilly will develop the bio-markers. An advantage of the technology is that it can be used on blood. Blood samples are routinely used, of course, for diagnosing a number of (infectious) diseases − but the current techniques obtain only a limited amount of information from the sample. Peakadilly’s bio-markers should make it possible to detect diseases more quickly (giving medical treatment a much greater chance of success) and to gear the therapy to the patient more effectively.

Start-up

Since the invention of the technology in 2001, the research team and VIB’s technology transfer team have been working on the development of a patented technology and product platform. When the technology and its product potential were presented in an early stage to a select group of (bio)pharmaceutical firms, the need for such a technology and products proved to be so large that R&D collaborations at a value of around 2 million euro were quickly established with 3 well-known firms.

These collaborations made it possible to house the technology in a new start-up enterprise: Peakadilly. The new company will be led by Koen Kas, who was a member of VIB’s tech-transfer team and fully involved in the development of the platform. The new CEO holds a doctorate in the bio-medical sciences, is an instructor at Ghent and Harvard Universities, and has previously held management positions in research at Tibotec, Virco and Galapagos.

Peakadilly will start out in the VIB bio-incubator, located in the Technology Park of Ghent University in Zwijnaarde. Among others, 4 VIB employees − all with extensive company experience − are transferring to Peakadilly to give the company a flying start. This start-up team will then be enlarged further. In addition, the company maintains its good relationship with the VIB department at Ghent University, where the technology was first developed and where it is being further developed with a team of 12 researchers.

Rudy Dekesyer | alfa
Further information:
http://www.vib.be

More articles from Life Sciences:

nachricht Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg

nachricht Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>